Standard BioTools Inc. (LAB) Financial Statements
Standard BioTools Inc. (LAB) reported trailing twelve-month revenue of $84.6M (down 4.8% year on year) and net income of $84.9M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$82.6M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
LABStandard BioTools Inc.Follow LAB — free
—
Price chart with a free account
- Market cap
- 237.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42.9 | 52.3 | 71.2 | 116.5 | 114.7 | 104.4 | 101.9 | 113.0 | 117.2 | 138.1 | 130.6 | 97.9 | 106.3 | 91.0 | 85.3 | 84.6 | |
| Gross profit | 29.7 | 37.0 | 52.6 | 76.9 | 71.7 | 63.3 | 56.9 | 61.6 | 64.3 | — | — | 37.1 | 50.5 | 44.9 | 42.5 | 42.7 | |
| Research & development | 13.9 | 16.6 | 20.0 | 43.4 | 39.3 | 38.4 | 30.8 | 30.0 | 31.6 | 36.5 | 37.9 | 37.4 | 25.9 | 28.8 | 26.0 | 18.4 | |
| Operating income | -18.6 | -18.1 | -18.7 | -51.8 | -50.2 | -73.2 | -58.4 | -48.2 | -51.8 | -51.0 | -67.5 | -116.2 | -76.6 | -127.5 | -110.2 | -95.5 | |
| Pre-tax income | -22.3 | -18.9 | -16.4 | -57.7 | -54.8 | -80.2 | -63.8 | -61.4 | -66.7 | -54.1 | -63.7 | -192.9 | -74.2 | -90.4 | -96.7 | -91.0 | |
| Income tax | 0.2 | 0.1 | 0.1 | -4.9 | -1.5 | -4.2 | -3.3 | -2.4 | -1.9 | -1.1 | -4.4 | -2.8 | 0.5 | 0.5 | -37.9 | -37.0 | |
| Net income | -22.5 | -19.0 | -16.5 | -52.8 | -53.3 | -76.0 | -60.5 | -59.0 | -64.8 | -53.0 | -59.2 | -190.1 | -74.7 | -138.9 | -74.9 | 84.9 | |
| Diluted EPS ($) | -1.81 | -0.86 | -0.65 | -1.90 | -1.86 | -2.62 | -1.84 | -1.49 | -0.97 | -0.74 | -0.78 | -2.43 | -0.94 | -0.52 | -0.20 | 0.22 | |
| Diluted shares (mn) | — | — | — | — | — | — | — | — | — | — | 75.8 | 78.3 | 79.2 | 353.2 | 381.6 | — |
USD millions · SEC XBRL
Standard BioTools Inc. — questions
- What is Standard BioTools Inc.'s revenue?
- $84.6M over the twelve months to 2026-06-30, down 4.8% year on year, from its 10-Q and 10-K filings.
- What is Standard BioTools Inc.'s net income?
- $84.9M over the twelve months to 2026-06-30.
- What is Standard BioTools Inc.'s free cash flow?
- -$82.6M over the twelve months to 2026-06-30.
- What are Standard BioTools Inc.'s diluted earnings per share?
- $0.22 over the twelve months to 2026-06-30.
Every figure on this page comes from Standard BioTools Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.